Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 14/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | PDE4A | P27815 | 9/20 | 0.82 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.82 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597430 | 0.91 | ADORA2B (0.82) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9429985 | 0.88 | PDE4A (0.85) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11073850 | 0.88 | ADORA2B (0.78) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL4623640 | 0.87 | ADORA2A (0.76) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11665017 | 0.85 | ADORA2B (0.72) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11455885 | 0.82 | ADORA2B (0.69) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7597424 | 0.81 | ADORA2A (0.67) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5134359 | 0.77 | ADORA2A (0.66) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5667530 | 0.76 | ADORA2A (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL669007 | 0.76 | ADORA2B (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1623223-A2 | FLUORESCENTLY TAGGED LIGANDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2006-02-08 | — | — | EP | claimed |
| JP-3677286-B2 | — | — | 2005-07-27 | — | — | JP | claimed |
| WO-2004088312-A2 | FLUORESCENTLY TAGGED LIGANDS | UNIVERSITY OF NOTTINGHAM (GB) | 2004-10-14 | — | — | WO | claimed |
| EP-0811623-B1 | Xanthine derivatives with end-aminated alkynol side chains | HOECHST AG (DE) | 2001-04-04 | — | — | EP | claimed |
| EP-0725782-A1 | NOVEL A 1 ADENOSINE RECEPTOR AGONISTS AND ANTIAGONISTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1995011904-A1 | NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTIAGONISTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1995-05-04 | — | — | WO | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| US-4965271-A | Method of inhibiting the activity of leukocyte derived cytokines | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1990-10-23 | — | — | US | claimed |
| US-4883801-A | Xanthine derivative pest control agents | THE GENERAL HOSPITAL CORPORATION (US) | 1989-11-28 | — | — | US | claimed |
| EP-0167566-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | SUNSHINE ABRAHAM (US) | 1987-06-29 | — | — | EP | claimed |
| EP-0193599-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| WO-1986001724-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-03-27 | — | — | WO | claimed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | claimed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
| JP-2025420-A | — | — | None | — | — | JP | disclosed |
| JP-56045474-A | — | — | None | — | — | JP | disclosed |
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240381918-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2024-11-21 | — | — | US | disclosed |
| US-12089621-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230354865-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2023-11-09 | — | — | US | disclosed |
| US-11793224-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230085907-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2023-03-23 | — | — | US | disclosed |
| US-11533940-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220071259-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2022-03-10 | — | — | US | disclosed |
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | disclosed |
| US-8871751-B2 | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-28 | — | — | US | disclosed |
| US-8603555-B2 | Methods for quantifying the complete nutritional value of a standard equivalent unit of the nutritional value of one serving of fruits and vegetables (SFV)and for fortifying a base food to contain same for human consumption | INNOCENZI MARK A (US) | 2013-12-10 | — | — | US | disclosed |
| US-8153781-B2 | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120027897-A1 | Methods For Quantifying The Complete Nutritional Value Of A Standard Equivalent Unit Of The Nutritional Value Of One Serving Of Fruits & Vegetables (SFV)And For Fortifying A Base Food To Contain Same For Human Consumption | INNOCENZI MARK A (US) | 2012-02-02 | — | — | US | disclosed |
| US-8053007-B2 | Compositions and methods for fortifying a base food to contain the complete nutritional value of a standard equivalent unit of the nutritional value of one serving of fruits and vegetables (“SFV”) for human consumption | Innocenzi, Mark (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110250318-A1 | COMPOSITIONS AND METHODS FOR FORTIFYING A BASE FOOD TO CONTAIN THE COMPLETE NUTRITIONAL VALUE OF ONE SERVING OF FRUITS AND VEGTABLES (\"SFV\") FOR HUMAN CONSUMPTION | INNOCENZI MARK | 2011-10-13 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1196050-B2 | COMPOSITIONS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | FOLGERS COFFEE CO (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2170401-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1322185-B1 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT | PROCTER & GAMBLE (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090291972-A1 | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-11-26 | — | — | US | disclosed |
| CN-100531600-C | Hypoglycemic reaction compositions | PROCTER & GAMBLE (US) | 2009-08-26 | — | — | CN | disclosed |
| WO-2009006046-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1622908-B1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1904020-A2 | NEW SLIMMING COSMETIC COMPOSITIONS | Sederma S.A.S. (FR) | 2008-04-02 | — | — | EP | disclosed |
| CN-101133834-A | Compositions, kits and methods for providing and maintaining energy and mental alertness | PROCTER & GAMBLE (US) | 2008-03-05 | — | — | CN | disclosed |
| WO-2007010478-A2 | SLIMMING COSMETIC COMPOSITIONS | SEDERMA (FR) | 2007-01-25 | — | — | WO | disclosed |
| US-20060211045-A1 | Fluorescently tagged ligands | CELLAURA TECHNOLOGIES LIMITED (GB) | 2006-09-21 | — | — | US | disclosed |
| EP-1623223-A2 | FLUORESCENTLY TAGGED LIGANDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2006-02-08 | — | — | EP | disclosed |
| CN-1633244-A | Aqueous chondro protective compositions having defined pH limitations for efficacious delivery | PROCTER & GAMBLE (US) | 2005-06-29 | — | — | CN | disclosed |
| EP-1014995-A4 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | ADERIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6815446-B1 | ADMINISTERING 8-AMINO-XANTHINE DERIVATIVE AS ANTIASTHMATIC OR ANTIDIARRHEA AGENT | VANDERBILT UNIVERSITY | 2004-11-09 | — | — | US | disclosed |
| US-6806270-B2 | XANTHINE DERIVATIVES, SUCH AS 3-ISOBUTYL-8-PYRROLIDINYLXANTHINE; TREATING ASTHMA, DIARRHEA, ETC. | VANDERBILT UNIVERSITY | 2004-10-19 | — | — | US | disclosed |
| WO-2004088312-A2 | FLUORESCENTLY TAGGED LIGANDS | UNIVERSITY OF NOTTINGHAM (GB) | 2004-10-14 | — | — | WO | disclosed |
| CN-1498084-A | Low glycemic response compositions | 宝洁公司 | 2004-05-19 | — | — | CN | disclosed |
| US-6703056-B2 | .01-10% OF ARABINOGALACTAN, AND ZINC, IRON, MAGNESIUM, CALCIUM, SELENIUM, IODINE, OR FLUORINE | THE PROCTER + GAMBLE CO. | 2004-03-09 | — | — | US | disclosed |
| EP-1372411-A1 | LOW GLYCEMIC RESPONSE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-0503563-B1 | Novel 8-substituted purines as selective adenosine receptor agents | MERRELL PHARMA INC (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6616955-B2 | Free of milk base solids; especially fruit juice | THE PROCTOR & GAMBLE CO. | 2003-09-09 | — | — | US | disclosed |
| CN-1438892-A | Low carbony drate compositions, kits thereof, and methods of use | PROCTER & GAMBLE (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1436072-A | Composition, kits, and methods for promoting defined health benefits | PROCTER & GAMBLE (US) | 2003-08-13 | — | — | CN | disclosed |
| CN-1431908-A | Kits and methods for optimizing efficacy of chondroprotective compsns. | PROCTER & GAMBLE (US) | 2003-07-23 | — | — | CN | disclosed |
| EP-1322184-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1322185-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087904-A1 | Selective antagonists of A2B adenosine receptors | VANDERBILT UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| EP-1196050-B1 | COMPOSITIONS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | PROCTER & GAMBLE (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030069202-A1 | Compositions, kits, and methods for promoting defined health benefits | PROCTER & GAMBLE COMPANY, THE | 2003-04-10 | — | — | US | disclosed |
| EP-1208100-B1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | UNIV VANDERBILT (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1289532-A2 | LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE | The Procter & Gamble Company (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289384-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED PH LIMITATIONS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289510-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| CN-1390096-A | Compositions, Kits and methods for providing and maintaining energy and mental alertness | PROCTER & GAMBLE (US) | 2003-01-08 | — | — | CN | disclosed |
| US-20020187219-A1 | Low glycemic response compositions | THE PROCTER & GAMBLE CO. | 2002-12-12 | — | — | US | disclosed |
| WO-2002078469-A1 | LOW GLYCEMIC RESPONSE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020136802-A1 | Beverage compositions comprising arabinogalactan and defined minerals | THE PROCTER & GAMBLE CO. | 2002-09-26 | — | — | US | disclosed |
| US-20020132780-A1 | Low carbohydrate compositions, kits thereof, and methods of use | SD IP HOLDINGS COMPANY | 2002-09-19 | — | — | US | disclosed |
| US-20020122847-A1 | Beverage compositions comprising palatable calcium and magnesium sources | PROCTER & GAMBLE COMPANY, THE | 2002-09-05 | — | — | US | disclosed |
| US-20020110632-A1 | Beverage compositions comprising arabinogalactan and defined vitamins | THE PROCTER & GAMBLE CO. | 2002-08-15 | — | — | US | disclosed |
| US-6420374-B1 | PENTOXIFYLLINE. | FRED HUTCHINSON CANCER RESEARCH CENTER | 2002-07-16 | — | — | US | disclosed |
| WO-2002052959-A2 | BEVERAGE COMPOSITIONS COMPRISING PALATABLE CALCIUM AND MAGNESIUM SOURCES | THE PROCTER & GAMBLE COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6413558-B1 | MIXTURE OF MONOSACCHARIDES, DISACCHARIDES AND MALTODEXTRIN | THE PROCTOR & GAMBLE CO. | 2002-07-02 | — | — | US | disclosed |
| EP-0969843-B1 | ANTITUSSIVE COMPOSITIONS CONTAINING THEOBROMINE | KORBONITS DEZSO (HU) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208100-A1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | VANDERBILT UNIVERSITY (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1196050-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6372723-B1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2002-04-16 | — | — | US | disclosed |
| WO-2002026055-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026053-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6348470-B1 | ALLEVIATE COUGH WITH THEOBROMINE | GAINE, INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | HOECHST AKTIENGESELLSCHAFT | 2002-01-24 | — | — | US | disclosed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | disclosed |
| WO-2001093847-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093831-A2 | LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093701-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED PH LIMITATIONS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | disclosed |
| WO-2001016134-A1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | VANDERBILT UNIVERSITY (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001005253-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1019426-A1 | NOVEL A 1? ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | THE UNIVERSITY OF FLORIDA (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0969843-A2 | ANTITUSSIVE COMPOSITIONS CONTAINING THEOBROMINE | Korbonits, Dezso (HU) | 2000-01-12 | — | — | EP | disclosed |
| US-5998387-A | N6-(EPOXYCYCLOALKYL) ADENOSINE COMPOUND AND PREPARATION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5965555-A | TREATMENT AND/OR PROPHYLAXIS OF CEREBROVASCULAR DISORDERS CHARACTERIZED BY DAMAGE CAUSED BY ISCHEMIA AND SUBSEQUENT NECROTIC DESTRUCTION OF NERVE CELLS(NEURONS) | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0552712-B1 | 8-(1-Aminocycloalkyl)-1,3-dialkylxanthine derivatives as antagonists adenosine receptors | FOSCAMA BIOMED CHIM FARMA (IT) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998042322-A2 | ANTITUSSIVE COMPOSITIONS | KORBONITS DEZSO (HU) | 1998-10-01 | — | — | WO | disclosed |
| US-5736528-A | CARDIOTONIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5668139-A | XANTHINE DERIVATIVES | UNIVERSITY OF FLORDIA RESEARCH FOUNDATION, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997024363-A1 | NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF FLORIDA (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5641773-A | ADMINISTERING COMBINATION OF TAT INHIBITOR AND NF-KB INHIBITOR | DANA-FARBER CANCER INSTITUTE (US) | 1997-06-24 | — | — | US | disclosed |
| US-5631260-A | Xanthine epoxides as A1 adenosine receptor agonists and antagonists | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0279079-B1 | Purine derivatives as interleukin-1 inhibitors | HOECHST MARION ROUSSEL INC (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0725782-A1 | NOVEL A 1 ADENOSINE RECEPTOR AGONISTS AND ANTIAGONISTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5545627-A | VASODILATORS, DIURETICS, IMMUNOSUPPRESSANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0484785-B1 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST ROUSSEL PHARMA (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0374808-B1 | Xanthin derivatives having an adenosin-antagonist activity | BOEHRINGER INGELHEIM KG (DE) | 1996-04-17 | — | — | EP | disclosed |
| EP-0483634-B1 | An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside | HOECHST ROUSSEL PHARMA (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | disclosed |
| US-5453426-A | Sulfur-containing xanthine derivatives as adenosine antagonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-26 | — | — | US | disclosed |
| US-5446046-A | 1,3-dipropyl-8-(3-oxatricyclo(3,1,2,0(2,4-))oct6(7)-Yl)-xanthine used to treat cadiac arrhythmias | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995011904-A1 | NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTIAGONISTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| US-5409935-A | Inhibit formation of free radicals | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0344288-B1 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | HOECHST ROUSSEL PHARMA (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0369744-B1 | Xanthine derivatives, process for their preparation and pharmaceutical compositions | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1994-09-21 | — | — | EP | disclosed |
| US-5321029-A | Vascular and skin disorders; bronchodilator | BEECHAM-WUELFING GMBH & CO.K.G. (DE) | 1994-06-14 | — | — | US | disclosed |
| US-5298508-A | Compounds as ligands for cardiovascular disorders or stimulant of immunology | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-03-29 | — | — | US | disclosed |
| CN-1082047-A | 8-(the amino cycloalkyl of 1-) 1,3-dialkyl xanthine derivative | FOSCAMA BIOMED CHIM FARMA (IT) | 1994-02-16 | — | — | CN | disclosed |
| CN-1082047-A | 8-(the amino cycloalkyl of 1-) 1,3-dialkyl xanthine derivative | FOSCAMA BIOMED CHIM FARMA (IT) | 1994-02-16 | — | — | CN | disclosed |
| US-5272153-A | Method of inhibiting the activity of leukocyte derived cytokines | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5208240-A | Alzeheimer's, cardiovascular, respiratory | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-05-04 | — | — | US | disclosed |
| US-5196430-A | 7-(oxoalkyl) 1,3-dialkyl xanthines | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-03-23 | — | — | US | disclosed |
| US-5196429-A | Method of inhibiting the activity of leukocyte derived cytokines | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0503563-A2 | Novel 8-substituted purines as selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0493682-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0490181-A1 | Use of xanthines for preparation of a medicament having immunosuppressing activity | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0484785-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0483634-A2 | An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-06 | — | — | EP | disclosed |
| US-5098996-A | Fluorination of compounds for use in diagnosis of nuclear medicine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-03-24 | — | — | US | disclosed |
| US-5096906-A | Interleukin antagonist, antiinflammatory | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0344288-A4 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | — | 1992-01-15 | — | — | EP | disclosed |
| US-5039666-A | Using 7-oxoalkyl-1,3-dialkyl xanthine compound | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4968672-A | DRUG DELIVERY; DIURETICS, KIDNEY DISORDERS, HYPOTENSIVE AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-06 | — | — | US | disclosed |
| WO-1990012797-A1 | SULFER-CONTAINING XANTHINE DERIVATIVES AS ADENOSIN ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1990-11-01 | — | — | WO | disclosed |
| US-4965271-A | Method of inhibiting the activity of leukocyte derived cytokines | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0374808-A2 | Xanthin derivatives having an adenosin-antagonist activity | BOEHRINGER INGELHEIM KG (DE) | 1990-06-27 | — | — | EP | disclosed |
| EP-0268585-B1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| EP-0369744-A2 | Xanthine derivatives, process for their preparation and pharmaceutical compositions | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| JP-H0225420-A | CONTROLLED-RELEASE ADMINISTRATION FORM HAVING RESTRICTED MOISTURE CONTENT | EURO CELTIQUE SA | 1990-01-26 | — | — | JP | disclosed |
| EP-0344288-A1 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4883801-A | Xanthine derivative pest control agents | THE GENERAL HOSPITAL CORPORATION (US) | 1989-11-28 | — | — | US | disclosed |
| WO-1989005145-A1 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-06-15 | — | — | WO | disclosed |
| US-4833146-A | BRAINS, BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| EP-0279079-A2 | Purine derivatives as interleukin-1 inhibitors | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-08-24 | — | — | EP | disclosed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| US-4696932-A | ANTIALLERGENS, ANTIHISTAMINES, CARDIOTONIC AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-09-29 | — | — | US | disclosed |
| US-4696932-A | ANTIALLERGENS, ANTIHISTAMINES, CARDIOTONIC AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0198921-A4 | BIOLOGICALLY-ACTIVE XANTHINE DERIVATIVES. | US COMMERCE (US) | 1987-03-16 | — | — | EP | disclosed |
| EP-0198921-A4 | BIOLOGICALLY-ACTIVE XANTHINE DERIVATIVES. | US COMMERCE (US) | 1987-03-16 | — | — | EP | disclosed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | disclosed |
| EP-0198921-A1 | BIOLOGICALLY-ACTIVE XANTHINE DERIVATIVES | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1986-10-29 | — | — | EP | disclosed |
| EP-0198921-A1 | BIOLOGICALLY-ACTIVE XANTHINE DERIVATIVES | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4612315-A | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1986-09-16 | — | — | US | disclosed |
| US-4612315-A | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0193599-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-09-10 | — | — | EP | disclosed |
| WO-1986002551-A1 | BIOLOGICALLY-ACTIVE XANTHINE DERIVATIVES | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1986-05-09 | — | — | WO | disclosed |
| WO-1986002551-A1 | BIOLOGICALLY-ACTIVE XANTHINE DERIVATIVES | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1986-05-09 | — | — | WO | disclosed |
| WO-1986001724-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
| US-4291037-A | PROMOTING THE FLOW OF BLOOD THROUGH SKELETAL MUSCLES VASODILATORS | Wulfing, Johann A. (DE) | 1981-09-22 | — | — | US | disclosed |
| JP-S5645474-A | PRODUCTION OF 5-OXOHEXYL-DIALKYLXANTHINE | SHIRATORI SEIYAKU KK | 1981-04-25 | — | — | JP | disclosed |
| US-4242345-A | VASODILATORS | Wulfing, Johann A. (DE) | 1980-12-30 | — | — | US | disclosed |
| US-4120947-A | Xanthine compounds and method of treating bronchospastic and allergic diseases | COOPER LABORATORIES, INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4089959-A | Long-acting xanthine bronchodilators and antiallergy agents | COOPER LABORATORIES, INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-3998953-A | 1,3,7-Trisubstitued xanthine peripheral vasodilators | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-21 | — | — | US | disclosed |
| US-3998953-A | 1,3,7-Trisubstitued xanthine peripheral vasodilators | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | ADORA1, ADORA2A, ADORA3 | ADORA2B 9/4885ADORA2A 2/4885PDE4A 338/4885 |
| US-20090291972-A1 | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer | PGR, ESR1, CYP19A1 | ADORA2B 486/4885ADORA2A 566/4885PDE4A 1654/4885 |
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | PER2, NCOR2, NR4A2 | ADORA2B 672/4885ADORA2A 254/4885PDE4A 216/4885 |
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | EPX, XDH, MPO | ADORA2B 163/4885ADORA2A 112/4885PDE4A 74/4885 |
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | ADORA2B 1369/4885ADORA2A 2335/4885PDE4A 3601/4885 |
| US-20030087904-A1 | Selective antagonists of A2B adenosine receptors | ADORA2B, ADORA1, ADORA2A | ADORA2B 1/4885ADORA2A 3/4885PDE4A 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.